Modeling Parkinson's disease pathology in human dopaminergic neurons by sequential exposure to α-synuclein fibrils and proinflammatory cytokines.


Journal

Nature neuroscience
ISSN: 1546-1726
Titre abrégé: Nat Neurosci
Pays: United States
ID NLM: 9809671

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 29 05 2023
accepted: 28 08 2024
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 8 10 2024
Statut: aheadofprint

Résumé

Lewy bodies (LBs), α-synuclein-enriched intracellular inclusions, are a hallmark of Parkinson's disease (PD) pathology, yet a cellular model for LB formation remains elusive. Recent evidence indicates that immune dysfunction may contribute to the development of PD. In this study, we found that induced pluripotent stem cell (iPSC)-derived human dopaminergic (DA) neurons form LB-like inclusions after treatment with α-synuclein preformed fibrils (PFFs) but only when coupled to a model of immune challenge (interferon-γ or interleukin-1β treatment) or when co-cultured with activated microglia-like cells. Exposure to interferon-γ impairs lysosome function in DA neurons, contributing to LB formation. The knockdown of LAMP2 or the knockout of GBA in conjunction with PFF administration is sufficient for inclusion formation. Finally, we observed that the LB-like inclusions in iPSC-derived DA neurons are membrane bound, suggesting that they are not limited to the cytoplasmic compartment but may be formed due to dysfunctions in autophagy. Together, these data indicate that immune-triggered lysosomal dysfunction may contribute to the development of PD pathology.

Identifiants

pubmed: 39379564
doi: 10.1038/s41593-024-01775-4
pii: 10.1038/s41593-024-01775-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
pubmed: 9278044 doi: 10.1038/42166
Baba, M. et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884 (1998).
pubmed: 9546347 pmcid: 1858234
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211 (2003).
pubmed: 12498954 doi: 10.1016/S0197-4580(02)00065-9
Rajput, A. H., Offord, K. P., Beard, C. M. & Kurland, L. T. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann. Neurol. 16, 278–282 (1984).
pubmed: 6333204 doi: 10.1002/ana.410160303
Braak, H., Sandmann-Keil, D., Gai, W. & Braak, E. Extensive axonal Lewy neurites in Parkinson’s disease: a novel pathological feature revealed by α-synuclein immunocytochemistry. Neurosci. Lett. 265, 67–69 (1999).
pubmed: 10327208 doi: 10.1016/S0304-3940(99)00208-6
Wakabayashi, K. et al. The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495–508 (2013).
pubmed: 22622968 doi: 10.1007/s12035-012-8280-y
Kim, W. S., Kagedal, K. & Halliday, G. M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther. 6, 73 (2014).
pubmed: 25580161 pmcid: 4288216 doi: 10.1186/s13195-014-0073-2
Engelhardt, E. & Gomes, M. D. M. Lewy and his inclusion bodies: discovery and rejection. Dement. Neuropsychol. 11, 198–201 (2017).
pubmed: 29213511 pmcid: 5710688 doi: 10.1590/1980-57642016dn11-020012
Glausier, J. R., Konanur, A. & Lewis, D. A. Factors affecting ultrastructural quality in the prefrontal cortex of the postmortem human brain. J. Histochem. Cytochem. 67, 185–202 (2019).
pubmed: 30562121 doi: 10.1369/0022155418819481
Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099–1109 (2019).
pubmed: 31235907 doi: 10.1038/s41593-019-0423-2
Soper, J. H. et al. α-Synuclein–induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell 19, 1093–1103 (2008).
pubmed: 18172022 pmcid: 2262993 doi: 10.1091/mbc.e07-08-0827
Gai, W. et al. In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 166, 324–333 (2000).
pubmed: 11085897 doi: 10.1006/exnr.2000.7527
Forno, L. S. & Norville, R. L. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol. 34, 183–197 (1976).
pubmed: 178142 doi: 10.1007/BF00688674
Frigerio, R. et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol. Aging 32, 857–863 (2011).
pubmed: 19560232 doi: 10.1016/j.neurobiolaging.2009.05.019
Monaco, A. & Fraldi, A. Protein aggregation and dysfunction of autophagy-lysosomal pathway: a vicious cycle in lysosomal storage diseases. Front. Mol. Neurosci. 13, 37 (2020).
pubmed: 32218723 pmcid: 7079699 doi: 10.3389/fnmol.2020.00037
Klein, A. D. & Mazzulli, J. R. Is Parkinson’s disease a lysosomal disorder? Brain 141, 2255–2262 (2018).
pubmed: 29860491 pmcid: 6061679 doi: 10.1093/brain/awy147
Durcan, T. M. & Fon, E. A. The three ‘P’s of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev. 29, 989–999 (2015).
pubmed: 25995186 pmcid: 4441056 doi: 10.1101/gad.262758.115
Boman, A. et al. Distinct lysosomal network protein profiles in parkinsonian syndrome cerebrospinal fluid. J. Parkinsons Dis. 6, 307–315 (2016).
pubmed: 27061067 pmcid: 4927933 doi: 10.3233/JPD-150759
Sato, S. et al. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice. Sci. Rep. 8, 2813 (2018).
pubmed: 29434298 pmcid: 5809579 doi: 10.1038/s41598-018-21325-w
Navarro-Romero, A., Montpeyo, M. & Martinez-Vicente, M. The emerging role of the lysosome in Parkinson’s disease. Cells 9, 2399 (2020).
Eskelinen, E. L. et al. Role of LAMP-2 in lysosome biogenesis and autophagy. Mol. Biol. Cell 13, 3355–3368 (2002).
pubmed: 12221139 pmcid: 124165 doi: 10.1091/mbc.e02-02-0114
Eskelinen, E. L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol. Asp. Med. 27, 495–502 (2006).
doi: 10.1016/j.mam.2006.08.005
Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657–673 (2022).
pubmed: 35246670 pmcid: 8895080 doi: 10.1038/s41577-022-00684-6
Matheoud, D. et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1
pubmed: 31316206 doi: 10.1038/s41586-019-1405-y
Panagiotakopoulou, V. et al. Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells. Nat. Commun. 11, 5163 (2020).
pubmed: 33057020 pmcid: 7560616 doi: 10.1038/s41467-020-18755-4
Ahmadi Rastegar, D. et al. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis. 8, 34 (2022).
pubmed: 35347144 pmcid: 8960803 doi: 10.1038/s41531-022-00297-9
Bayati, A. et al. Rapid macropinocytic transfer of alpha-synuclein to lysosomes. Cell Rep. 40, 111102 (2022).
pubmed: 35858558 doi: 10.1016/j.celrep.2022.111102
Kawanokuchi, J. et al. Production of interferon-γ by microglia. Mult. Scler. 12, 558–564 (2006).
pubmed: 17086900 doi: 10.1177/1352458506070763
Wang, X. & Suzuki, Y. Microglia produce IFN-γ independently from T cells during acute toxoplasmosis in the brain. J. Interferon Cytokine Res. 27, 599–605 (2007).
pubmed: 17651021 doi: 10.1089/jir.2006.0157
Lv, D. et al. Combining interferon-γ release assays with lymphocyte enumeration for diagnosis of Mycobacterium tuberculosis infection. J. Int. Med. Res. 48, 300060520925660 (2020).
pubmed: 32527178 doi: 10.1177/0300060520925660
Yang, Y., Wang, H. J., Hu, W. L., Bai, G. N. & Hua, C. Z. Diagnostic value of interferon-gamma release assays for tuberculosis in the immunocompromised population. Diagnostics (Basel) 12, 453 (2022).
Fang, C. et al. IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. Oncoimmunology 10, 1962591 (2021).
pubmed: 34408924 pmcid: 8366549 doi: 10.1080/2162402X.2021.1962591
Rezai-Zadeh, K., Gate, D. & Town, T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J. Neuroimmune Pharm. 4, 462–475 (2009).
doi: 10.1007/s11481-009-9166-2
Yang, Q., Wang, G. & Zhang, F. Role of peripheral immune cells-mediated inflammation on the process of neurodegenerative diseases. Front. Immunol. 11, 582825 (2020).
pubmed: 33178212 pmcid: 7593572 doi: 10.3389/fimmu.2020.582825
Lees, J. R. & Cross, A. H. A little stress is good: IFN-γ, demyelination, and multiple sclerosis. J. Clin. Invest. 117, 297–299 (2007).
pubmed: 17273549 pmcid: 1783822 doi: 10.1172/JCI31254
Duffy, S. S., Lees, J. G. & Moalem-Taylor, G. The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult. Scler. Int. 2014, 285245 (2014).
pubmed: 25374694 pmcid: 4211315
Molteni, M. & Rossetti, C. Neurodegenerative diseases: the immunological perspective. J. Neuroimmunol. 313, 109–115 (2017).
pubmed: 29153601 doi: 10.1016/j.jneuroim.2017.11.002
De Simone, R., Levi, G. & Aloisi, F. Interferon γ gene expression in rat central nervous system glial cells. Cytokine 10, 418–422 (1998).
pubmed: 9632527 doi: 10.1006/cyto.1997.0314
Suzuki, Y., Claflin, J., Wang, X., Lengi, A. & Kikuchi, T. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int. J. Parasitol. 35, 83–90 (2005).
pubmed: 15619519 doi: 10.1016/j.ijpara.2004.10.020
Liu, X. & Quan, N. Microglia and CNS interleukin-1: beyond immunological concepts. Front. Neurol. 9, 8 (2018).
pubmed: 29410649 pmcid: 5787061 doi: 10.3389/fneur.2018.00008
Cekanaviciute, E. & Buckwalter, M. S. Astrocytes: integrative regulators of neuroinflammation in stroke and other neurological diseases. Neurotherapeutics 13, 685–701 (2016).
pubmed: 27677607 pmcid: 5081110 doi: 10.1007/s13311-016-0477-8
Bonvento, G. & Bolanos, J. P. Astrocyte-neuron metabolic cooperation shapes brain activity. Cell Metab. 33, 1546–1564 (2021).
pubmed: 34348099 doi: 10.1016/j.cmet.2021.07.006
Mulica, P., Grunewald, A. & Pereira, S. L. Astrocyte-neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective. Front. Endocrinol. (Lausanne) 12, 668517 (2021).
pubmed: 34025580 doi: 10.3389/fendo.2021.668517
Zhang, L. et al. Cortical thinning and cognitive impairment in Parkinson’s disease without dementia. IEEE/ACM Trans. Comput. Biol. Bioinform. 15, 570–580 (2018).
pubmed: 29610105 pmcid: 5918696 doi: 10.1109/TCBB.2015.2465951
Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047 (1997).
pubmed: 9197268 doi: 10.1126/science.276.5321.2045
Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318–1320 (1998).
pubmed: 9809558 doi: 10.1038/3311
Luk, K. C. et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051–20056 (2009).
pubmed: 19892735 pmcid: 2785290 doi: 10.1073/pnas.0908005106
Bieri, G., Gitler, A. D. & Brahic, M. Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. Neurobiol. Dis. 109, 219–225 (2018).
pubmed: 28323023 doi: 10.1016/j.nbd.2017.03.007
Freeman, D. et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS ONE 8, e62143 (2013).
pubmed: 23634225 pmcid: 3636263 doi: 10.1371/journal.pone.0062143
Jiang, P., Gan, M., Yen, S. H., McLean, P. J. & Dickson, D. W. Impaired endo-lysosomal membrane integrity accelerates the seeding progression of α-synuclein aggregates. Sci. Rep. 7, 7690 (2017).
pubmed: 28794446 pmcid: 5550496 doi: 10.1038/s41598-017-08149-w
Vergarajauregui, S., Connelly, P. S., Daniels, M. P. & Puertollano, R. Autophagic dysfunction in mucolipidosis type IV patients. Hum. Mol. Genet. 17, 2723–2737 (2008).
pubmed: 18550655 pmcid: 2515373 doi: 10.1093/hmg/ddn174
Pajares, M. et al. Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy 14, 1310–1322 (2018).
pubmed: 29950142 pmcid: 6103698 doi: 10.1080/15548627.2018.1474992
Dodson, M., Anandhan, A., Zhang, D. D. & Madhavan, L. An NRF2 perspective on stem cells and ageing. Front. Aging 2, 690686 (2021).
pubmed: 36213179 pmcid: 9536878 doi: 10.3389/fragi.2021.690686
Joshi, C. S., Mora, A., Felder, P. A. & Mysorekar, I. U. NRF2 promotes urothelial cell response to bacterial infection by regulating reactive oxygen species and RAB27B expression. Cell Rep. 37, 109856 (2021).
pubmed: 34686330 doi: 10.1016/j.celrep.2021.109856
Park, J. Y., Kim, S., Sohn, H. Y., Koh, Y. H. & Jo, C. TFEB activates Nrf2 by repressing its E3 ubiquitin ligase DCAF11 and promoting phosphorylation of p62. Sci. Rep. 9, 14354 (2019).
pubmed: 31586112 pmcid: 6778067 doi: 10.1038/s41598-019-50877-8
Abokyi, S., Shan, S. W., To, C. H., Chan, H. H. & Tse, D. Y. Autophagy upregulation by the TFEB inducer trehalose protects against oxidative damage and cell death associated with NRF2 inhibition in human RPE cells. Oxid. Med. Cell. Longev. 2020, 5296341 (2020).
pubmed: 32774677 pmcid: 7396061 doi: 10.1155/2020/5296341
Suzen, S., Tucci, P., Profumo, E., Buttari, B. & Saso, L. A pivotal role of Nrf2 in neurodegenerative disorders: a new way for therapeutic strategies. Pharmaceuticals (Basel) 15, 692 (2022).
Cortes, C. J. & La Spada, A. R. TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities. Neurobiol. Dis. 122, 83–93 (2019).
pubmed: 29852219 doi: 10.1016/j.nbd.2018.05.012
Huang, J. et al. LC3B, a protein that serves as an autophagic marker, modulates angiotensin II-induced myocardial hypertrophy. J. Cardiovasc. Pharmacol. 66, 576–583 (2015).
pubmed: 26284810 doi: 10.1097/FJC.0000000000000306
Runwal, G. et al. LC3-positive structures are prominent in autophagy-deficient cells. Sci. Rep. 9, 10147 (2019).
pubmed: 31300716 pmcid: 6625982 doi: 10.1038/s41598-019-46657-z
Guerra, F. et al. Synergistic effect of mitochondrial and lysosomal dysfunction in Parkinson’s disease. Cells 8, 452 (2019).
Fan, Y. et al. Perillaldehyde ameliorates Aspergillus fumigatus keratitis by activating the Nrf2/HO-1 signaling pathway and inhibiting Dectin-1-mediated inflammation. Invest. Ophthalmol. Vis. Sci. 61, 51 (2020).
pubmed: 32579678 pmcid: 7415897 doi: 10.1167/iovs.61.6.51
Fuyuno, Y. et al. Perillaldehyde inhibits AHR signaling and activates NRF2 antioxidant pathway in human keratinocytes. Oxid. Med. Cell. Longev. 2018, 9524657 (2018).
pubmed: 29643980 pmcid: 5832143 doi: 10.1155/2018/9524657
Tang, L. F. et al. Perillaldehyde mitigates ionizing radiation-induced intestinal injury by inhibiting ferroptosis via the Nrf2 signaling pathway. Mol. Nutr. Food Res. 67, e2300232 (2023).
pubmed: 37658487 doi: 10.1002/mnfr.202300232
Zheng, W., Liu, B. & Shi, E. Perillaldehyde alleviates spinal cord ischemia-reperfusion injury via activating the Nrf2 pathway. J. Surg. Res. 268, 308–317 (2021).
pubmed: 34399353 doi: 10.1016/j.jss.2021.06.055
Zhang, J. et al. Lysosomal LAMP proteins regulate lysosomal pH by direct inhibition of the TMEM175 channel. Mol. Cell 83, 2524–2539 (2023).
pubmed: 37390818 pmcid: 10528928 doi: 10.1016/j.molcel.2023.06.004
Kaushik, S. & Cuervo, A. M. The coming of age of chaperone-mediated autophagy. Nat. Rev. Mol. Cell Biol. 19, 365–381 (2018).
pubmed: 29626215 pmcid: 6399518 doi: 10.1038/s41580-018-0001-6
Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 361, 1651–1661 (2009).
pubmed: 19846850 pmcid: 2856322 doi: 10.1056/NEJMoa0901281
Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132, 1783–1794 (2009).
pubmed: 19286695 pmcid: 2702833 doi: 10.1093/brain/awp044
Kim, S. et al. GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers. Proc. Natl Acad. Sci. USA 115, 798–803 (2018).
pubmed: 29311330 pmcid: 5789900 doi: 10.1073/pnas.1700465115
Gan-Or, Z., Liong, C. & Alcalay, R. N. GBA-associated Parkinson’s disease and other synucleinopathies. Curr. Neurol. Neurosci. Rep. 18, 44 (2018).
pubmed: 29884970 doi: 10.1007/s11910-018-0860-4
Gan-Or, Z., Alcalay, R. N., Makarious, M. B., Scholz, S. W. & Blauwendraat, C. Classification of GBA variants and their effects in synucleinopathies. Mov. Disord. 34, 1581–1582 (2019).
pubmed: 31769092 doi: 10.1002/mds.27803
Navarro-Romero, A. et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. NPJ Parkinsons Dis. 8, 126 (2022).
pubmed: 36202848 pmcid: 9537323 doi: 10.1038/s41531-022-00397-6
Smith, J. A., Das, A., Ray, S. K. & Banik, N. L. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 87, 10–20 (2012).
pubmed: 22024597 doi: 10.1016/j.brainresbull.2011.10.004
Mahul-Mellier, A. L. et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. USA 117, 4971–4982 (2020).
pubmed: 32075919 pmcid: 7060668 doi: 10.1073/pnas.1913904117
Fares, M. B., Jagannath, S. & Lashuel, H. A. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat. Rev. Neurosci. 22, 111–131 (2021).
pubmed: 33432241 doi: 10.1038/s41583-020-00416-6
Lam, I. et al. Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions. Neuron 112, 2886–2909.e16 (2024).
pubmed: 39079530 pmcid: 11377155 doi: 10.1016/j.neuron.2024.06.002
Zhang, X. et al. Aged microglia promote peripheral T cell infiltration by reprogramming the microenvironment of neurogenic niches. Immun. Ageing 19, 34 (2022).
pubmed: 35879802 pmcid: 9310471 doi: 10.1186/s12979-022-00289-6
Frucht, D. M. et al. IFN-γ production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22, 556–560 (2001).
pubmed: 11574279 doi: 10.1016/S1471-4906(01)02005-1
Kasen, A. et al. Upregulation of α-synuclein following immune activation: possible trigger of Parkinson’s disease. Neurobiol. Dis. 166, 105654 (2022).
pubmed: 35143968 doi: 10.1016/j.nbd.2022.105654
Scudamore, O. & Ciossek, T. Increased oxidative stress exacerbates α-synuclein aggregation in vivo. J. Neuropathol. Exp. Neurol. 77, 443–453 (2018).
pubmed: 29718367 doi: 10.1093/jnen/nly024
Duffy, P. E. & Tennyson, V. M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson’s disease. J. Neuropathol. Exp. Neurol. 24, 398–414 (1965).
doi: 10.1097/00005072-196507000-00003
Watanabe, I., Vachal, E. & Tomita, T. Dense core vesicles around the Lewy body in incidental Parkinson’s disease: an electron microscopic study. Acta Neuropathol. 39, 173–175 (1977).
pubmed: 197775 doi: 10.1007/BF00703325
Galloway, P., Mulvihill, P. & Perry, G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am. J. Pathol. 140, 809 (1992).
pubmed: 1314025 pmcid: 1886359
Colosimo, C., Hughes, A., Kilford, L. & Lees, A. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 74, 852–856 (2003).
pubmed: 12810766 pmcid: 1738521 doi: 10.1136/jnnp.74.7.852
Huynh, K. K. et al. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 26, 313–324 (2007).
pubmed: 17245426 pmcid: 1783450 doi: 10.1038/sj.emboj.7601511
Morell, C. et al. Up-regulated expression of LAMP2 and autophagy activity during neuroendocrine differentiation of prostate cancer LNCaP cells. PLoS ONE 11, e0162977 (2016).
pubmed: 27627761 pmcid: 5023108 doi: 10.1371/journal.pone.0162977
Martinez-Vicente, M. et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118, 777–788 (2008).
pubmed: 18172548 pmcid: 2157565
Malkus, K. A. & Ischiropoulos, H. Regional deficiencies in chaperone-mediated autophagy underlie α-synuclein aggregation and neurodegeneration. Neurobiol. Dis. 46, 732–744 (2012).
pubmed: 22426402 pmcid: 3352979 doi: 10.1016/j.nbd.2012.03.017
Saha, S., Buttari, B., Profumo, E., Tucci, P. & Saso, L. A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer’s and Parkinson’s diseases. Front. Cell. Neurosci. 15, 787258 (2021).
pubmed: 35126058 doi: 10.3389/fncel.2021.787258
Mohamed, N. V. et al. Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy. Brain Commun. 3, fcab223 (2021).
pubmed: 34632384 pmcid: 8495137 doi: 10.1093/braincomms/fcab223
Miura, Y. et al. Engineering brain assembloids to interrogate human neural circuits. Nat. Protoc. 17, 15–35 (2022).
pubmed: 34992269 doi: 10.1038/s41596-021-00632-z
Birey, F. et al. Assembly of functionally integrated human forebrain spheroids. Nature 545, 54–59 (2017).
pubmed: 28445465 pmcid: 5805137 doi: 10.1038/nature22330
Wen, W. et al. Enhanced generation of integration-free iPSCs from human adult peripheral blood mononuclear cells with an optimal combination of episomal vectors. Stem Cell Rep. 6, 873–884 (2016).
doi: 10.1016/j.stemcr.2016.04.005
Chen, C. X.-Q. et al. A multistep workflow to evaluate newly generated iPSCs and their ability to generate different cell types. Methods Protoc. 4, 50 (2021).
pubmed: 34287353 pmcid: 8293472 doi: 10.3390/mps4030050
Maneca, D.-L. et al. Production of recombinant α synuclein monomers and preformed fibrils (PFFs). https://doi.org/10.5281/zenodo.3738335 (2019).
Del Cid Pellitero, E. et al. Quality control characterization of α-synuclein preformed fibrils (PFFs). https://doi.org/10.5281/zenodo.3738340 (2019).
Feller, B. et al. α-Synuclein preformed fibrils bind to β-neurexins and impair β-neurexin-mediated presynaptic organization. Cells 12, 1083 (2023).
Bayati, A. et al. Visualization of α-synuclein trafficking via nanogold labeling and electron microscopy. STAR Protoc. 4, 102113 (2023).
pubmed: 36861831 pmcid: 9988663 doi: 10.1016/j.xpro.2023.102113
Jefri, M. et al. Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells. Stem Cells Transl. Med. 9, 697–712 (2020).
pubmed: 32154672 pmcid: 7214648 doi: 10.1002/sctm.18-0180
Chen, X. R. et al. Induction of dopaminergic or cortical neuronal progenitors from iPSCs. https://doi.org/10.5281/zenodo.3364831 (2019).
Sheta, R. et al. Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons. Sci. Rep. 12, 17176 (2022).
pubmed: 36229560 pmcid: 9562300 doi: 10.1038/s41598-022-22158-4
Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785–798 (2013).
pubmed: 23764284 pmcid: 3751803 doi: 10.1016/j.neuron.2013.05.029
Meijer, M. et al. A single-cell model for synaptic transmission and plasticity in human iPSC-derived neurons. Cell Rep. 27, 2199–2211 (2019).
pubmed: 31091456 doi: 10.1016/j.celrep.2019.04.058
Chen, Y. et al. Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. Eur. J. Neurosci. 49, 510–524 (2019).
pubmed: 30472757 doi: 10.1111/ejn.14286
Chen, C. X. et al. A multistep workflow to evaluate newly generated iPSCs and their ability to generate different cell types. Methods Protoc. 4, 50 (2021).
Chen, C. X. et al. Generation of homozygous PRKN, PINK1 and double PINK1/PRKN knockout cell lines from healthy induced pluripotent stem cells using CRISPR/Cas9 editing. Stem Cell Res. 62, 102806 (2022).
pubmed: 35561458 doi: 10.1016/j.scr.2022.102806
Tong, L., Balazs, R., Soiampornkul, R., Thangnipon, W. & Cotman, C. W. Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol. Aging 29, 1380–1393 (2008).
pubmed: 17467122 doi: 10.1016/j.neurobiolaging.2007.02.027
Stojkovska, I. & Mazzulli, J. R. Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue. STAR Protoc. 2, 100372 (2021).
pubmed: 33733241 pmcid: 7941090 doi: 10.1016/j.xpro.2021.100372
Cantu, D. A. et al. EZcalcium: open-source toolbox for analysis of calcium imaging data. Front. Neural Circuits 14, 25 (2020).
pubmed: 32499682 pmcid: 7244005 doi: 10.3389/fncir.2020.00025
1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).
doi: 10.1038/nature09534
Labno, C. Two ways to count cells with ImageJ. https://cpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/c/2275/files/2020/01/cell_counting_automated_and_manual.pdf
Legland, D., Arganda-Carreras, I. & Andrey, P. MorphoLibJ: integrated library and plugins for mathematical morphology with ImageJ. Bioinformatics 32, 3532–3534 (2016).
pubmed: 27412086 doi: 10.1093/bioinformatics/btw413
Peters, A. E. et al. The impact of aging on macroautophagy in the pre-ovulatory mouse oocyte. Front. Cell Dev. Biol. 9, 691826 (2021).
pubmed: 34268312 pmcid: 8277196 doi: 10.3389/fcell.2021.691826

Auteurs

Armin Bayati (A)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. armin.bayati@mail.mcgill.ca.

Riham Ayoubi (R)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Adriana Aguila (A)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Cornelia E Zorca (CE)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Ghislaine Deyab (G)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Chanshuai Han (C)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Sherilyn Junelle Recinto (SJ)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Emmanuelle Nguyen-Renou (E)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Cecilia Rocha (C)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Gilles Maussion (G)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Wen Luo (W)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Irina Shlaifer (I)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Emily Banks (E)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Ian McDowell (I)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Esther Del Cid Pellitero (E)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Xue Er Ding (XE)

Computational Biology Department, Carnegie Mellon University, Pittsburgh, PA, USA.

Behrang Sharif (B)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Philippe Séguéla (P)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Moein Yaqubi (M)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Carol X-Q Chen (CX)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Zhipeng You (Z)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Narges Abdian (N)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Heidi M McBride (HM)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Edward A Fon (EA)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Jo Anne Stratton (JA)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Thomas M Durcan (TM)

The Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC, Canada.

Patrick C Nahirney (PC)

Division of Medical Sciences, University of Victoria, Victoria, BC, Canada.

Peter S McPherson (PS)

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. peter.mcpherson@mcgill.ca.

Classifications MeSH